Extract
Alpha-1-antitrypsin (AAT) is a serine proteinase inhibitor, the main function of which is to inhibit neutrophil elastase (NE) activity, but it also regulates several immune and inflammatory responses [1]. Deficiency of the protein (alpha-1-antitrypsin deficiency or AATD) is a well-known genetic condition associated with an increased risk of developing pulmonary emphysema and liver disease [2, 3]. It has been hypothesised that it is associated with other respiratory diseases, such as asthma or bronchiectasis [4], and it has also been linked with a potential increase of the risk of some types of cancer, although the information available is sparse [5].
Abstract
Alpha-1-antitrypsin deficiency has been linked with a potential increase of the risk of some types of cancer; international prospective registries are key to shed light on this important aspect https://bit.ly/3AIApov
Footnotes
Conflict of interest: M. Miravitlles has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Kamada, Sandoz, Zambon, CSL Behring, Grifols and Novartis, consulting fees from AstraZeneca, Atriva Therapeutics, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Inhibrx, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, Spin Therapeutics, ONO Pharma, pH Pharma, Palobiofarma SL, Takeda, Novartis, Sanofi and Grifols, and research grants from Grifols. M. Barrecheguren has received speaker fees from Grifols, Menarini, CSL Behring, GSK and Boehringer Ingelheim, and consulting fees from GSK, Novartis, CSL Behring and Boehringer Ingelheim.
- Received June 23, 2022.
- Accepted June 30, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org